Creative Disruption Forum on Cell & Gene Therapies: Making your company more investable

Date: Wednesday, 22 May 2024 

Time: 10:00 AM – 5:30 PM BST 

Location: Wellcome Collection,  Burrooughs Room, 183 Euston Road, London, NW1 2BE 

 

Event Overview 

Join us at the upcoming Creative Disruption Forum on Cell & Gene Therapies, an exclusive event for C-level executives and leaders in the cell and gene therapy (CGT) space. This event is dedicated to fostering innovating thinking and engaging conversations about what makes biotech companies investable, accelerating the journey from lab to market. 

Learn more and register here

 

Why Attend? 

• Expert Insights: Learn from the experiences of seasoned industry professionals and thought leaders during our insightful conversations 
• Interesting Topics: Explore interesting topics such as how to make biotech companies more investable, the complexities of CGT development and manufacturing and how to overcome them, strategies for successful commercialization of CGTs 
• Interactive Workshop: Participate in our Creative Disruption workshop to brainstorm and address common challenges in the CGT sector 
• Networking Opportunities: Build lasting relationships with peers and key industry players during our networking sessions

 

Featured Speakers: 

• Dominic Schmidt, Ph.D., General Partner, Advent Life Sciences 
• Christiane Bardroff, Chief Operating Officer (COO), Rentschler Biopharma 
• Christopher Bohl, Scientific Advisor, BioIVT 
• Nicki Redfern, Director, NJ Redfern Ltd 
• David Venables, CEO, Laverock Therapeutics 

 

Moderated by: Professor Tony Sedgwick, Founder @thoughtdisruptor.com 

 

Agenda

10:30 - 10:50 am	Opening remarks with Tony Sedgwick
10:50 - 11:10 am	"A conversation with" Dominic Schmidt: What is hot for investors in CGT?
11:10 - 11:30 am	"A conversation with" Christiane Bardroff: The complexities of CGT development and manufacturing and how to overcome these challenges
11:30 - 11:50 am	"A conversation with" Christopher Bohl: Could liver tox derail your CGT program? What researchers look for when choosing hepatocytes for hepatoxicity evaluations?
11:50 am - 12:20 pm	"A conversation with" Nicki Redfern: The CGT commercial journey - what are the lessons learned?
12:20 - 12:40 pm	"A conversation with" David Venables: Lessons learned from a life of adventures in the world of cell and gene therapy
12:40 - 1:00 pm	Panel discussion with Dominic Schmidt, Christiane Bardroff, Nicki Redfern, David Venables - What does success look like for CGT biotechs?
1:00 - 2:00 pm	Networking Lunch
2:00 - 3:15 pm	Creative Disruption Workshop
3:15 - 3:45 pm	Coffee Break
3:45 - 4:45 pm	Group Leader Presentations
4:45 - 5:30 pm	Tony Sedgwick, speakers and participants summarize the learnings of the day